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Abstract
 
The use of peptide–human histocompatibility leukocyte antigen (HLA) class I tetrameric com-
plexes to identify antigen-specific CD8
 
1
 
 T cells has provided a major development in our un-
derstanding of their role in controlling viral infections. However, questions remain about the
exact function of these cells, particularly in HIV infection. Virus-specific cytotoxic T lympho-
cytes exert much of their activity by secreting soluble factors such as cytokines and chemo-
 
kines. We describe here a method that combines the use of tetramers and intracellular staining to
examine the functional heterogeneity of antigen-specific CD8
 
1
 
 T cells ex vivo. After stimula-
 
tion by specific peptide antigen, secretion of interferon (IFN)-
 
g
 
, tumor necrosis factor (TNF)-
 
a
 
,
macrophage inflammatory protein (MIP)-1
 
b
 
, and perforin is analyzed by FACS
 
®
 
 within the
tetramer-positive population in peripheral blood. Using this method, we have assessed the
functional phenotype of HIV-specific CD8
 
1
 
 T cells compared with cytomegalovirus (CMV)-
specific CD8
 
1
 
 T cells in HIV chronic infection. We show that the majority of circulating
CD8
 
1
 
 T cells specific for CMV and HIV antigens are functionally active with regards to the
secretion of antiviral cytokines in response to antigen, although a subset of tetramer-staining
 
cells was identified that secretes IFN-
 
g
 
 and MIP-1
 
b
 
 but not TNF-
 
a
 
. However, a striking finding
is that HIV-specific CD8
 
1
 
 T cells express significantly lower levels of perforin than CMV-spe-
cific CD8
 
1
 
 
 
T cells. This lack of perforin is linked with persistent CD27 expression on HIV-
specific cells, suggesting impaired maturation, and specific lysis ex vivo is lower for HIV-spe-
cific compared with CMV-specific cells from the same donor. Thus, HIV-specific CD8
 
1
 
 T
cells are impaired in cytolytic activity.
Key words: cytotoxic T lymphocytes • HIV • cytokines • tetramers • perforin
 
Introduction
 
CTLs have been shown to play a major role in the control
of persisting viruses, including EBV, CMV, and HIV (for a
review, see reference 1). However, the exact mechanisms
by which CTLs exert their antiviral activity remain un-
clear. Several methods have been developed to analyze hu-
man CTL responses and to study their involvement in the
immune response to virus infection. The best-established
methods are based on the ability of CTLs to lyse appropri-
ate target cells in vitro. This can be performed under limit-
 
Address correspondence to Andrew J. McMichael, MRC Human Immu-
nology Unit, Institute of Molecular Medicine, John Radcliffe Hospital,
Headington, Oxford OX3 9DS, UK. Phone: 44-1865-222-336; Fax: 44-
1865-222-502; E-mail: andrew.mcmichael@ndm.ox.ac.uk 
64
 
Functional Studies of HIV-specific CD8
 
1
 
 T Cells
 
ing dilution conditions (limiting dilution assay [LDA]
 
1
 
) to
provide a quantitative measurement of the antigen-specific
CTL precursor cells that are able to grow and divide in
vitro (1). The use of other recently developed techniques,
including the quantification of individual TCR tran-
scripts (2, 3), measurement of cytokine production by CD8
 
1
 
T cells (4), and the IFN-
 
g
 
 enzyme-linked immunospot
(ELISPOT) assay (5), has shown that the LDA may signifi-
cantly underestimate the true frequency of circulating
CD8
 
1
 
 T cells with specificity for viral antigens (6, 7). More
recently, a technique in which tetramers of fluorochrome-
bound HLA class I molecules assembled with a single anti-
genic peptide are used to stain CD8
 
1
 
 T cells with specific-
ity for the particular peptide–HLA complex (8) has proved
a major advance in the study of antigen-specific T cells.
Analysis of tetramer-positive CD8
 
1
 
 T cells by flow cytom-
etry provides a method that reliably quantitates the number
of specific CD8
 
1
 
 T cells present in peripheral blood, and
can provide additional information about their phenotype
through costaining for cell surface markers, including
markers of activation (6, 9), apoptosis (10), and TCR V
 
b
 
usage (11).
All of these methods address different aspects of antigen-
specific CD8
 
1
 
 T cell activity. LDA measures the lytic abil-
ity of specific CTLs, but is also dependent on their ability
to grow and divide in tissue culture conditions. ELISPOT
assays examine the ability of antigen-specific CD4
 
1
 
 or
CD8
 
1
 
 cells to secrete a single cytokine, usually IFN-
 
g
 
, on
contact with their cognate antigen, but do not address their
lytic function or secretion of other soluble factors. It is also
not clear that all antigen-specific CD8
 
1
 
 cells are able to
produce IFN-
 
g
 
 on specific stimulation. This assumption
arises largely from studies of individual CTL clones (12,
13), and remains to be unequivocally established for the
polyclonal response to human viral infection. The use of
peptide–HLA tetrameric complexes to stain antigen-spe-
cific CD8
 
1
 
 T cells is based on the ability of their TCR to
interact specifically with a complex of the appropriate HLA
molecule assembled with a relevant peptide with sufficient
avidity to allow read-out by FACS
 
®
 
 analysis. Recently,
several questions have been raised about the functional sig-
nificance of the tetramer-staining CD8
 
1
 
 T cell population
(14–17). The functional relevance of tetramer staining is
suggested by the correlation with other assays of CTL
function, including direct lysis in a 
 
51
 
Cr-release assay (18),
LDA and ELISPOT assays (6, 7), and the ability of tet-
ramer-sorted cells to differentiate into individual CTL
clones (19, 20). However, studies in a murine model of
lymphocytic choriomeningitis virus (LCMV) infection in
which CD4
 
1
 
 T cell help was deficient revealed that the
circulating tetramer-staining CD8
 
1
 
 cell population was
functionally defective and unable to mediate protection
 
(15). In HIV infection, a cardinal feature is a progressive
defect in CD4
 
1
 
 T cell function, which is most marked for
HIV-specific CD4
 
1
 
 responses (21). It has therefore been
proposed that the ultimate failure of the CD8
 
1
 
 T cell re-
sponse to control HIV replication arises because the lack of
CD4
 
1
 
 T cell help renders these cells nonfunctional (16).
We have addressed the functional phenotype of the HIV-
specific tetramer-positive CD8
 
1
 
 T cell population by de-
veloping a method that combines the precision of tetramer
quantification with detailed information about individual
CD8
 
1
 
 T cell function.
The release of soluble mediators by CTLs in response to
the presentation of specific antigen by an APC is critical to
their role in control of infection. These molecules include
cytokines, such as IL-2, IFN-
 
g
 
, or TNF-
 
a
 
, chemokines
(e.g., regulated upon activation, normal T cell expressed
and secreted [RANTES]), and cytotoxins (e.g., perforin).
The properties of these different mediators are highly heter-
ogeneous, contributing to the diversity of CTL function.
For human CTL clones, the pattern of cytokine release may
differ between individual CTLs, in a similar manner to that
described for CD4
 
1
 
 T cell lines and clones. The use of
FACS
 
®
 
 analysis of cells subjected to intracellular staining for
cytokines and chemokines in response to mitogen stimula-
tion, which are retained within the cell using brefeldin A,
has been of great value in the functional characterization of
CD4
 
1
 
 T cells, including those derived directly from pe-
ripheral blood (22). Here, we describe a method that com-
bines tetramer staining with measurement of the production
of cytokines, chemokines, and perforin. This provides, for
the first time, a means of examining the functional pheno-
type of circulating CD8
 
1
 
 T cells with specificity for a par-
ticular viral antigen at a single cell level. We use this tech-
nique to examine the secretion of a panel of soluble factors
by CD8
 
1
 
 T cells responding to HIV and CMV antigens in
HIV-infected subjects. The panel consisted of four soluble
factors with different activities: (a) IFN-
 
g
 
, known for in-
ducing cellular antiviral proteins (23) and its ability to acti-
vate macrophages (24); (b) TNF-
 
a
 
, which is able to inhibit
viral gene expression and replication (23); (c) macrophage
inflammatory protein (MIP)-1
 
b
 
, a chemokine that also sup-
presses HIV infection (25) through competition for the
HIV coreceptor CC chemokine receptor 5 (CCR5); and
(d) perforin, which promotes cell death through pore for-
mation in the cell membrane (26). We show that the opti-
mal method for stimulating the release of these factors is
contact between the CD8
 
1
 
 T cells and their specific anti-
gen. Using this technique, we show that the majority of tet-
ramer-staining cells specific for both HIV and CMV anti-
gens in HIV-infected patients are functionally active with
regard to cytokine and chemokine secretion. However,
HIV-specific CD8
 
1
 
 T cells are characterized by a striking
lack of intracellular perforin staining, which is reflected in
relatively poor ex vivo killing and correlates with persistent
CD27 expression, a marker of cell differentiation. This ap-
parent defect in cytolytic activity may contribute to the de-
cline in CD8
 
1
 
-mediated suppression of HIV replication
with disease progression.
 
1
 
Abbreviations used in this paper:
 
 APC, allophycocyanin; ELISPOT, en-
zyme-linked immunospot; HAART, highly active antiretroviral therapy;
LCMV, lymphocytic choriomeningitis virus; LDA, limiting dilution as-
say; MIP, macrophage inflammatory protein; PerCP, peridinin chloro-
phyll protein; RANTES, regulated on activation, normal T cell expressed
and secreted. 
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Materials and Methods
 
Study Subjects and Samples.
 
Samples were taken from HIV se-
ronegative volunteers, and from HIV-infected subjects attending
clinics in Oxford, London, San Diego, and New York who were
largely selected on the basis of previous studies demonstrating a
significant tetramer-staining CD8
 
1
 
 T cell population in their pe-
ripheral blood. These included patients taking highly active anti-
retroviral therapy (HAART) and long-term survivors with good
control of viral load in the absence of antiretroviral therapy. The
local Institutional Review Boards approved this study. CD4
 
1
 
 T
cell counts in the donors ranged between 200 and 1,200 cells/
 
m
 
l,
and viral loads between 
 
,
 
50 and 650,000 RNA copies/ml. HLA
typing was carried out by amplification refractory mutation sys-
tem (ARMS)-PCR using sequence-specific primers as described
previously (27). PBMCs were separated from heparinized blood,
and either studied fresh or cryopreserved for subsequent studies.
 
Generation of Antigen-specific
 
 
 
CD8
 
1
 
 Clones.
 
Virus-specific
CTL clones were generated from human PBLs by sorting using
peptide–HLA monomer-coated beads as described previously (20,
28). In brief, refolded biotinylated monomeric complexes were
bound to streptavidin-coated magnetic beads (Dynal) at 4
 
8
 
C over-
night. Beads were washed in cold RPMI 1640 (GIBCO BRL)
and incubated with PBMCs at 10 beads per tetramer-positive cell
(analyzed by FACS
 
®
 
 beforehand) for 20 min at 4
 
8
 
C. After exten-
sive washes, cells were plated in round-bottomed 96-well plates at
100 
 
m
 
l/well of the following cloning mixture: RPMI 1640, 10%
human serum (HS), 10
 
7
 
 irradiated PBMCs, PHA (5 
 
m
 
g/ml), and
three to five sorted CTLs per milliliter. Cloning plates were incu-
bated at 37
 
8
 
C in 5% CO
 
2
 
. After 4 d, Lymphocult-T (20%;
Biotest) was added to the wells. After an additional 10 d of incu-
bation, wells with substantial growth were expanded in 24-well
plates using the cloning mixture described above. Clones were se-
lected using cytotoxicity assay and tetramer staining. Selected
clones were restimulated when proliferation reached a plateau
(
 
z
 
1 mo after cloning), by adding 2 
 
3 
 
10
 
6
 
 irradiated PBMCs and
PHA (at 5 
 
m
 
g/ml final concentration). Resting clones (with low
CD69 expression level) were used for intracellular staining studies.
 
Antigens and Antibodies.
 
Peptides were synthesized by FMOC
chemistry, and corresponded to defined CTL epitopes (see Table
I). Anti-CD3 antibodies, OKT3, and anti-CD28 antibodies were
purchased from Ortho and Becton Dickinson, respectively. Anti-
CD8 (peridinin chlorophyll protein [PerCP]) and anti-CD69
(conjugated with FITC, PE, or allophycocyanin [APC]) antibod-
ies were purchased from Becton Dickinson. Anti-CD25 (FITC),
anti-CD27 (FITC), anti-CD28 (APC), anti-CD38 (APC), anti-
CD45RO (APC), anti-CD45RA (FITC), anti–HLA-DR (FITC),
and anti-Ki67 (FITC) antibodies were purchased from BD
PharMingen. Anti–IFN-
 
g
 
 (FITC), anti–MIP-1
 
b
 
 (FITC), and
anti–TNF-
 
a
 
 (FITC) mAbs were purchased from R&D Systems.
Antiperforin (FITC) and anti–TNF-
 
a
 
 (APC) mAbs were pur-
chased from BD PharMingen and Becton Dickinson, respec-
tively. Isotype control antibodies were purchased from Dako.
 
Preparation of HLA–Peptide Tetrameric Complexes.
 
The HLA
molecule heavy chain cDNAs were modified by substitution of
the transmembrane and cytosolic regions with a sequence encod-
ing the BirA biotinylation enzyme recognition site, as described
previously (8). These modified HLA heavy chains, and 
 
b
 
2-micro-
globulin, were synthesized in a prokaryotic expression system
(pET; R&D Systems), purified from bacterial inclusion bodies,
and allowed to refold with the relevant peptide by dilution. Re-
folded monomeric complexes were purified by FPLC and biotin-
ylated using BirA (Avidity), then combined with PE-labeled
streptavidin (Sigma-Aldrich) at a 4:1 molar ratio to form tet-
 
rameric HLA–peptide complexes (hereafter “tetramers”). The list
of tetramers used is given in Table I. Tetramers were titrated
against appropriate CTL clones to determine the dose that in-
duced maximal staining (19).
 
Cell Surface and Intracellular Cytokine Staining.
 
Specific clones
were incubated with one of the following: tetramers, OKT3
(Ortho) (coated onto the plate wells at 200 ng/ml for 2 h at 37
 
8
 
C
beforehand), autologous B cell lines (BCL) pulsed with specific
peptide at 20 
 
m
 
M, then washed before use (1:2 E/T ratio) or left
untreated (negative control) in RPMI 1640/10% FCS. Studies
were performed in the presence of brefeldin A (Sigma-Aldrich) at
a final concentration of 10 
 
m
 
g/ml, and anti-CD28 antibody at 3
mg/ml. Freshly purified or thawed cryopreserved PBMCs were
stained before activation with tetrameric complexes for 15 min at
378C. Cells were subsequently incubated with specific antigens at
10 mM final concentration, or OKT3 at 100 ng/ml final concen-
tration, or PBS (nonactivated cells), in RPMI 1640/10% FCS and
in the presence of anti-CD28 antibody (at 3 mg/ml) and left for
6 h or overnight at 378C. Brefeldin A (at 10 mg/ml final concentra-
tion) was added during the second hour of incubation. Nonacti-
vated PBMCs were then stained with tetrameric complexes for
15 min at 378C. Cells were washed in PBS, 0.5 mM EDTA, 1%
BSA, fixed, and permeabilized in FACS™ Permeabilizing Buffer
(Becton Dickinson) for 10 min. After washing, staining was per-
formed for 15 min at room temperature in the dark using a panel
of FITC-, PE-, PerCP-, or APC-conjugated antibodies. Cells
were then washed and stored in 5% formaldehyde at 48C until
flow cytometry analysis was performed, using a Becton Dickinson
FACSCalibur™ machine. Four-color stainings were usually car-
ried out on PBMC samples, using FITC-conjugated anti–IFN-g,
anti–TNF-a, anti–MIP-1b, or antiperforin antibodies to stain in-
tracellular cytokines, PE-tetramers to stain antigen-specific CD8
T cells, PerCP-conjugated anti-CD8 to facilitate the analysis, and
Table I. Peptides Corresponding to Defined CTL Epitopes
HLA type
specificity Virus Protein Epitope Sequence
A*0201 HIV Gag p17 77–85 SLYNTVATL
A*0201 HIV Pol 476–484 ILKEPVHGV
A*0201 CMV
Lower matrix
protein pp65 495–503 NLVPMVATV
A11 HIV Nef 73–82 QVPLRPMTYK
A*6802 HIV Pol 744–752 ETAYFILKL
B7 HIV Nef 128–137 TPGPGVRYPL
B7 CMV
Lower matrix
protein pp65 417–426 TPRVTGGGAM
B8 HIV Nef 89–97 FLKEKGGL
B8 HIV Gag p24 259–267 DIYKRWII
B*2705 HIV Gag p24 263–272 KRWIIMGLNK
B57 HIV Gag p24 163–174 KAFSPEVIPMF
B*5801 HIV Pol 244–252 IVLPEKDSW
Cw4 HIV Gag p17 28–36 KYRLKHLVW
A*6802/pol and Cw4/gag peptides are newly defined epitopes (Dong,
T., unpublished data).66 Functional Studies of HIV-specific CD81 T Cells
APC-conjugated anti-CD69 to assess cell activation, or APC-
conjugated anti–TNF-a for double cytokine stainings. Isotype
controls were carried out in each condition (activated or nonacti-
vated) and were used to define limits for cytokine production.
Perforin staining was generally carried out directly on whole
blood. Specific tetramers were added to 100 ml of whole blood
for 15 min at 378C, the lymphocytes were then fixed, and the red
blood cells were lysed using FACS™ Lysing Solution (Becton
Dickinson). Permeabilization and staining using specific antibod-
ies were carried out as above.
Fresh Cytotoxic Assay. HLA-matched EBV-transformed au-
tologous B cell lines were used as target cells in standard 51Cr-
release CTL assays. 51Cr labeling was performed for 1 h, after
which cells were pulsed for 1 h in the presence of specific pep-
tides and extensively washed in RPMI medium. 5 3 103 target
cells were aliquoted into microtiter plates. Controls included tar-
get cells incubated with medium or 10% Triton only. Freshly pu-
rified PBMCs were added to the targets at different E/T ratios, in
triplicate. Partial depletion of the antigen-specific CD81 T cells
was carried out by staining the cells with the relevant tetramers,
followed by MACS cell separation using anti-PE beads (Miltenyi
Biotec). Assay plates were incubated 5 h before harvest. Specific
51Cr release was calculated from the following equation: [(experi-
mental release 2 spontaneous release)/(maximum release 2
spontaneous release)] 3 100%.
Results
Combination of Tetramer Staining and Intracellular
Cytokine Staining
Tetramer Staining before Activation Permits Identification of
the Tetramer-positive Population despite TCR Downregulation.
A potential hindrance to functional studies of tetramer-
staining cells is that activation procedures needed to stimu-
late cytokine production will also lead to rapid down-
regulation of the TCR (29), with which the tetrameric
complexes interact to stain antigen-specific T cells. This
problem can be overcome by tetramer staining of the cells
before activation. Fig. 1 shows the staining of PBMCs from
a healthy CMV-positive HLA-B7 donor, in whom z1% of
the CD81 T cell population stains with an HLA-B7 CMV
tetramer. PBMCs were incubated overnight in the pres-
ence of either OKT3 or the CMV B7-restricted epitope
peptide. Significant downregulation of the TCR assessed
by the level of tetramer staining was seen both in cells
treated with OKT3 and, more dramatically, in the cells
stimulated with peptide. However, cells stained with tet-
ramers before activation maintained reasonable (although
slightly reduced) levels of tetramer staining despite activa-
tion, probably due to tetramer internalization (30). A clear
feature of the activated CD81 T cells is partial downregula-
tion of CD8, which is also most marked with peptide stim-
ulation; this can be used as an indicator of activation. Simi-
lar data were obtained with donors of different HLA type
and for CD81 T cells of different specificity (HIV or
CMV; data not shown).
Specific Peptide Provides Optimal Activation. Different
methods of T cell activation were studied to determine the
optimal protocol for intracellular cytokine staining. OKT3
is an antibody that activates T cells by binding to the CD3
molecule and cross-linking the TCR complex (31). Spe-
cific peptides are presented by the HLA molecules on
APCs among the PBMC population to the TCRs of spe-
cific CD81 T cells and induce activation. Since this inter-
action is reproduced when tetramers bind to the TCR-
appropriate T cells, we examined whether they could
directly influence T cell activation or interfere with activa-
tion of the cells induced by either peptide or OKT3. Fig. 2 A
shows the extent of activation of the CMV B7 tetramer-
staining population treated with tetramers alone or in com-
bination with either OKT3 or peptide, using the early acti-
vation marker CD69. Similar levels of CD69 upregulation
were observed using all three methods, confirming that tet-
ramers can directly activate T cells. Whereas activation lev-
els appeared to be identical, different profiles of IFN-g and
MIP-1b secretion were observed using intracellular stain-
Figure 1. Tetramer staining and cell activation. PBMCs
from a CMV-positive B7 donor were incubated for 12 h
with brefeldin A in the presence of PBS (no activation
control) (A and D), OKT3 (100 ng/ml) (B and C), or spe-
cific CMV B7 peptide (10 mM) (E and F). Tetramer stain-
ing was carried out either after overnight incubation (A, B,
D, and E) or before addition of the activators (C and F).
Percentages for tetramer-staining cells are shown. Cells
were fixed and analyzed by flow cytometry after staining
for CD8 surface molecules.67 Appay et al.
ing. This was particularly striking for IFN-g release, which
was very low using OKT3 or tetramers, but maximal when
triggered by specific peptide on APCs (Fig. 2 B). Com-
pared with IFN-g, higher levels of MIP-1b secretion were
observed in response to OKT3 or tetramers, but were
maximal if stimulated by the peptide-pulsed cells (Fig. 2
C). Thus, the optimal method of inducing cytokine release
from antigen-specific CD81 T cells appears to be the use of
specific peptides. Similar results were obtained with PB-
MCs from different donors (data not shown).
The Time Course of Cytokine and Chemokine Secretion by
Individual Virus-specific CTL Clones. The use of antigen-
specific CTL clones remains a key element in the study of
CTL function, although the physiological relevance of cells
that have been propagated and restimulated for weeks in
vitro may be questioned. We studied the intracellular stain-
ing profile of HIV-specific and CMV-specific CTL clones
that had been generated and cultured for several weeks; in-
tracellular cytokine studies were carried out at least 21 d af-
ter in vitro restimulation in order to study a resting cell
population. These clones were assessed for IFN-g and
MIP-1b secretion after stimulation using peptide-pulsed
APCs, OKT3 (coated onto culture wells), or specific tet-
ramers (Fig. 3 A). The results were very similar to those us-
ing PBMCs, namely that although the clones displayed rel-
atively similar levels of CD69 upregulation in response to
all three activators (data not shown), cytokine expression,
particularly IFN-g, was much greater when stimulated by
specific antigen presented by APCs.
We then used the clones for time course experiments
to identify the optimal time to measure cytokine and
chemokine secretion after stimulation with antigen-pulsed
APCs. As early as 1 h after activation, significant TNF-a
staining could be detected, which closely followed the rise
in CD69 expression (Fig. 3 B), whereas the production of
IFN-g and MIP-1b was relatively delayed. These factors
were mainly generated during the first 5–6 h after activa-
tion, after which staining for both CD69 and intracellular
cytokines reached a plateau. The increasing expression of
the soluble factors was inversely proportional to the CD8
staining, which decreased over time after stimulation. Sim-
ilar patterns of secretion were observed with other virus-
specific clones (data not shown), and experiments using
PBMCs showed low cytokine staining after 2 h but subse-
quently no differences between 6 h and overnight incuba-
tion (data not shown). Therefore, an incubation time of 6 h
was chosen for subsequent assays.
We also examined the production of MIP-1a by the
clones. The pattern of expression was similar to MIP-1b,
although the staining intensity was very low: the poor effi-
ciency of these antibodies for intracellular studies rendered
them inadequate for use in PBMC studies (data not
shown). Staining for RANTES was also assessed but led
to inappropriate staining increase, assumed to be due to
RANTES binding on the cell surface (data not shown).
Therefore, we used MIP-1b staining to represent the CC
chemokines that are able to suppress HIV replication (25).
HIV-specific CD81 T Cells in Chronic HIV Infection Are 
Functionally Active for Cytokine Secretion
Most Tetramer-staining HIV-specific and CMV-specific CD81
T Cells Express IFN-g, MIP-1b, and TNF-a on Activation,
but a Small Subpopulation Is TNF-a Negative. The optimized
protocol for combined tetramer and intracellular cyto-
kine staining described above was used to study the func-
tion of circulating CD81 T cells specific for HIV and CMV.
Fig. 4 shows representative results of intracellular staining
for IFN-g, MIP-1b, and TNF-a within the CMV (A) or
Figure 2. Comparison among peptide, OKT3, and tet-
ramer activation. PBMCs from a CMV-positive B7 donor
were incubated for 12 h with brefeldin A in the presence
of PBS (no activation control), specific CMV B7 peptide
(10 mM), OKT3 (100 ng/ml), or CMV B7 tetramers. Tet-
ramer staining was carried out after overnight incubation
for the no activation control or before addition of the acti-
vators for the “activated” cells. Cells were stained for
CD69 (A), IFN-g (B), and MIP-1b (C) and analyzed by
flow cytometry. Data show cells gated on the CMV B7
tetramer-positive population. Mean fluorescence intensity
is shown for each condition.68 Functional Studies of HIV-specific CD81 T Cells
Figure 3. Intracellular staining in CTL clones. (A) A
CMV-specific B7 clone was incubated for 12 h with
brefeldin A in the presence of PBS (no activation control),
specific antigen-pulsed APCs, OKT3 (coated onto the ex-
perimental wells), or CMV B7 tetramers. Intracellular
staining for IFN-g and MIP-1b was carried out, and the
cells were analyzed by flow cytometry. Mean fluorescence
intensity is shown for each condition. (B) An HIV-specific
Cw4-restricted CTL clone was incubated for various times
in the presence of brefeldin A and specific antigen-pulsed
APCs. Cells were stained and analyzed by flow cytometry.
CD8 staining (x) is expressed in mean fluorescence inten-
sity, and CD69 (s), IFN-g (d), TNF-a (m), and MIP-1b
(r) stainings are expressed in percentage of positive cells.
ing cells was identified that failed to produce TNF-a even
though they secreted IFN-g and MIP-1b and had upregu-
lated CD69. The size of the TNF-a–negative subpopula-
tion varied between 0 and 60% in different tetramer-stain-
ing populations. Double cytokine stainings confirmed that
these cells could still produce the other cytokines (data not
shown). Overall, these results clearly demonstrate that, in
chronically HIV-infected donors with a significant popula-
tion of HIV-specific or CMV-specific tetramer-staining
CD81 cells, the majority of these cells produce a range of
antiviral soluble factors in response to specific antigens.
However, 2 of the 15 HIV-specific populations we analyzed
(H9 and H14) showed much lower numbers of cytokine-
secreting cells (z25% of tetramer-positive cells). We are
currently in the process of investigating these cells further to
characterize their apparent defect in cytokine secretion.
The Cytokine Secretion of Antigen-specific CD81 T Cells Is
Not Affected by HAART. A cross-sectional study was car-
ried out using PBMC samples from eight HAART-treated
HIV-infected patients. Several investigators have demon-
strated that the frequency of HIV-specific CD81 T cells
usually declines to below detection after a few months on
antiretroviral therapy (32–35). However, we could study
HIV (B) specific CD81 T cell population of two different
donors. A slight decrease in the percentage of tetramer-pos-
itive cells was generally observed after stimulation. A small
proportion of the activated T cells may not stain brightly
enough to be gated among the tetramer-positive cells, or
some cells may have presented antigen to one another and
been lysed. However, the independent analysis of the tet-
ramer staining data and cytokine staining data suggest that
the gated tetramer-positive activated population is represen-
tative of the antigen-specific population as a whole. The cy-
tokine expression profile is remarkably similar between the
two viral specificities. After activation of the cells using spe-
cific antigens, the great majority of tetramer-staining cells
displayed reduced levels of CD8 and TCR expression, and
upregulation of CD69, indicating that most of the virus-
specific population was adequately activated. 21 HIV-
infected donors were studied, using the tetramers shown in
Table I (in total, 26 different tetramer-positive populations
were studied). In most donors, between 50 and 95% of the
activated virus-specific CD81 T cells were producing IFN-g
and MIP-1b (Table II). Interestingly, although most of
the antigen-specific CD81 T cells secreted TNF-a in paral-
lel with the other factors, a distinct subset of tetramer-stain-69 Appay et al.
CMV-specific CD81 T cells in these subjects, since their
numbers are maintained in HIV-infected subjects on anti-
retroviral therapy. Table III shows the results of cytokine
and chemokine production by CMV-specific CD81 T cell
populations from donors with either HLA-A2 or HLA-B7.
Both the frequency and cytokine profile of the CMV-spe-
cific CD81 T cells were unchanged in HAART-treated pa-
tients, and the proportion of TNF-a–negative tetramer-
positive cells did not differ from untreated donors. We
could also examine this question directly in four donors
who had maintained populations of HIV-specific tetramer-
staining cells in the range of 0.1–1.1% despite prolonged vi-
ral suppression on antiretroviral therapy (our unpublished
data); cytokine release from these cells was in a similar range
to that seen in most untreated donors. Taken together,
these data suggest that HAART has no direct influence on
the cytokine secretion of antigen-specific CD81 T cells.
HIV-specific CD81 T Cells Appear to Be at a Different Stage of 
Maturation from CMV-specific CD81 T Cells
HIV-specific CD81 T Cells Express Low Levels of Perforin.
We then studied the expression of perforin, which is in-
timately linked with cytolytic activity in virus-specific
CD81 T cells (26, 36). In contrast to the other factors stud-
ied, perforin staining does not require any activation before
the cells are permeabilized, implying that there are stores of
preformed perforin in antigen-specific CD81 T cells. In-
deed, perforin staining was often reduced after T cell acti-
vation of CTL clones or in PBMCs (data not shown), pre-
sumably due to release of the preformed perforin. 18
samples from chronically HIV-infected patients were co-
stained with HIV and/or CMV tetramers and antibodies to
perforin. Fig. 5 A shows a representative perforin staining
obtained with PBMCs from a single donor who had signif-
icant numbers of both HIV-specific and CMV-specific
CD81 T cell populations. A striking observation was that
the expression of perforin in HIV-specific CD81 T cells
was much lower than that detected in either the CMV-
specific CD81 T cells or the CD81 population as a whole.
Several antigen-specific CD81 T cell populations from dif-
ferent donors (A2 Gag, A2 Pol, A11 Nef, B7 Nef, B8 Gag,
B8 Nef, B8 p24, B27 Gag, B57 Gag, and B58 Pol for HIV,
and A2 and B7 for CMV) were stained for perforin to
compare perforin levels in HIV-specific, CMV-specific,
and total CD81 T cells (Fig. 5 B). This confirmed that
HIV-specific CD81 T cells are unusually low in perforin
compared with CMV-specific CD81 T cells, which more
closely resemble the rest of the CD81 T cell population.
HIV-specific Killing Ex Vivo Is Lower Than CMV-specific
Lysis from the Same Donor. The lack of perforin in HIV-
specific populations was correlated with decreased cytotoxic
activity compared with CMV-specific populations. Ex vivo
cytotoxic assays were carried out in two donors possessing
similar percentages of both HIV (A2 Gag, B27 Gag, and B8
Nef) and CMV (A2 CMV) tetramer-staining cells (Fig. 6 A).
In each case, the HIV-specific populations showed lower
levels of specific lysis compared with CMV-specific CD81 T
cells at the same E/T ratios, which approximately corre-
sponded to the proportions of perforin in each population.
HIV-specific CD81 T cells therefore appear to be less effi-
cient cytotoxic effectors. Depletion of the tetramer-staining
populations caused a significant reduction of specific killing
(Fig. 6 B), showing that the cytotoxicity observed is largely
due to the presence of the antigen-specific CD81 T cells.
Figure 4. Intracellular staining for IFN-g, MIP-1b, and
TNF-a in HIV-specific or CMV-specific CD81 T cells.
PBMCs from HIV-infected patients were incubated for 6 h
with brefeldin A in the presence of PBS (no activation) or
specific peptides (10 mM) (activation). Intracellular staining
for IFN-g, MIP-1b, and TNF-a was carried out, and the
cells were analyzed by flow cytometry. Cytokine staining
is shown on CMV (A) and HIV (B) specific CD81 T cell
populations gated using the tetramers (top). Percentages of
cells present in quadrants are shown. Representative data
are shown (see Table II).70 Functional Studies of HIV-specific CD81 T Cells
If low perforin levels in vivo are due to constant degran-
ulation in response to persistent viral antigens, then patients
with prolonged viral suppression after optimal antiretroviral
therapy would be expected to have restored perforin levels.
However, we were able to examine the perforin staining of
HIV-specific tetramer-staining populations in three donors
with undetectable viral loads for at least 4 yr on therapy
(our unpublished data), and this was in the range of 3–19%
(Fig. 5 B, arrows). This observation makes it unlikely that
repeated degranulation underlies the perforin defect we
have described.
Difference in the Expression of Maturation Markers between
CMV-specific and HIV-specific CD81 T Cells. To charac-
terize further the differences between HIV-specific and
CMV-specific CD81 T cells, we used cell surface markers
to assess their phenotype ex vivo. We found no obvious
differences in their activation status, assessed by the expres-
sion of CD69 (negative), CD25 (negative), HLA-DR (pos-
itive), and CD38 (mixed population) (data not shown).
Neither of these populations was proliferating, as measured
by general lack of Ki67 expression (data not shown). The
state of cell maturation was assessed using the markers
CD28, CD27, CD45RO, and CD45RA. The majority of
HIV-specific and CMV-specific CD81 T cells were nega-
tive for CD28 (Fig. 7 A), which has been shown to be
downregulated on effector cells (37). Perforin-producing
Table II. Cytokine Expression in Antigen-specific CD8 T Cells
Percentage of positive cells
Donor Specificity
IFN-g
positive
MIP-1b
positive
TNF-a
positive
H1 A2 gag 72 ND 48
H2 A2 gag 66 ND 29
H3 A2 gag 86 75 47
H4 A2 gag 86 85 25
H5 A2 gag 98 86 90
H6 A2 gag 80 80 80
H7 B8 gag 88 80 71
H8 B8 nef 78 ND ND
H9 B8 nef 25 40 20
H10 B8 nef 80 ND ND
H11 B8 nef 60 ND 45
H12 B8 p24 60 ND 45
H13 B27 gag 47 54 25
H14 B27 gag 24 21 14
H15 B57 gag 68 70 37
C1 A2 cmv 66 62 49
C2 A2 cmv 74 73 42
C3 A2 cmv 55 53 39
C4 A2 cmv 65 64 50
C5 A2 cmv 83 83 60
C6 A2 cmv 95 94 90
C7 B7 cmv 95 95 95
C8 B7 cmv 88 85 90
C9 B7 cmv 76 73 56
C10 B7 cmv 74 70 46
C11 B7 cmv 88 80 60
Intracellular staining for IFN-g, MIP-1b, and TNF-a was carried out
in combination with tetramer staining using samples from HIV-infected
patients. The table shows the cytokine expression in different antigen-
specific CD81 T cell populations stimulated with specific peptides.
Table III. Influence of HAART on CMV-specific CD8 T Cell 
Cytokine Expression
Percentage of positive cells
Patient
(HLA type)
Months of
treatment
Tetramer positive
in CD81
IFN-g
positive
MIP-1b
positive
TNF-a
positive
897 (A2) 0 1.4 66 62 49
6 2.8 70 61 47
10 2.4 74 65 50
13 2.2 84 77 62
912 (A2) 0 1.5 74 73 42
6 1.2 81 71 50
913 (A2) 0 3.3 55 53 39
1 6 4 8 98 36 6
1002 (A2) 5 0.6 61 58 37
11 0.2 65 64 50
17 0.3 63 64 50
23 0.3 70 70 40
31 0.5 73 65 45
1003 (B7) 12 2.3 76 73 56
31 3.5 75 60 67
1010 (B7) 4 3.3 74 70 46
17 3.4 74 70 54
24 2.9 60 66 40
31 3.5 67 68 45
2002 (A2) 5 5.5 83 83 60
17 6.4 80 78 58
2 3 5 7 98 75 5
29 8 89 ND 71
2003 (B7) 11 5.6 77 80 28
21 5.8 88 78 60
Intracellular staining for IFN-g, MIP-1b, and TNF-a was carried out
in combination with tetramer staining using samples from HAART-
treated HIV-infected patients. The table shows the cytokine expression
and tetramer numbers in CMV-specific CD81 T cells stimulated with
specific peptides.71 Appay et al.
cells were found among this population, as expected from
previous studies (38). However, CD27 expression differed
between HIV-specific and CMV-specific CD81 T cells, as
HIV-specific CD81 T cells were predominantly CD271
compared with CMV-specific CD81 T cells, which were
mainly CD272. HIV-specific CD81 T cells were generally
CD45RA2RO1 as described previously (32), but some
CMV-specific CD81 T cells expressed CD45RA (data not
shown). There was a strong inverse correlation between
perforin expression and CD27 expression, even when
comparing HIV-specific and CMV-specific populations
from the same donors, implying that perforin-producing
cells are CD272 (Fig. 7 B). CMV-specific CD81 T cells
therefore appear to be fully mature effector cells, as they are
both CD272 and CD282, and express perforin (37). In
contrast, HIV-specific CD81 T cells have not reached the
same stage of maturation as the CMV effectors, as they re-
tain CD27 and show low perforin expression.
Discussion
The technique we have described combines the advan-
tages provided by the tetramer technology of reliable iden-
tification and quantification of T cells of known specificity
together with information about their functional capac-
ity through intracytoplasmic staining for cytokines and
chemokines. This method has the potential to provide
valuable information about antigen-specific  T cells in a
range of conditions.
Specific antigens provided the best way to stimulate cy-
tokine secretion, and represent a more physiological activa-
tion method than PMA and ionomycin, commonly used in
intracellular cytokine staining studies; a recent report has
emphasized the difference between these compounds and
specific antigens, since they induce different pathways of
cytotoxity in CD81 T cells (39). We were able to bypass
the problem of TCR downregulation upon T cell activa-
tion by staining the cells with tetramers before stimulation.
Figure 5. Perforin staining in antigen-specific CD81 T cells. (A) Per-
forin intracellular staining was carried out in a sample from an HIV-
infected patient known to have both HIV-specific and CMV-specific CD81
T cell populations. Cells were stained with tetramers and directly stained
for perforin without cell activation. Both the total lymphocyte population
(top row) and the antigen-specific CD81 T cells (bottom rows) were
gated and analyzed for perforin staining. The data are expressed as percent-
ages of perforin-positive cells determined to be staining above the hori-
zontal limit. Similar observations were obtained with other donors who
also had both HIV-specific and CMV-specific CD81 T cell populations.
(B) Perforin intracellular staining was performed, as above, in samples
known to have either an HIV-specific or a CMV-specific CD8 T cell
population. Data are expressed in numbers of perforin-positive cells within
the relevant cell populations. 18, 18, and 13 samples are displayed for
whole, HIV-specific, and CMV-specific CD81 T cell populations, respec-
tively. Arrows indicate that samples come from HAART-treated donors.
Figure 6. Fresh cytotoxic assay with HIV-specific or CMV-specific
CD81 T cells from the same donors. (A) Cell frequency and percentage
of HIV-specific or CMV-specific CD81 T cells expressing perforin from
each donor. (B) Specific lysis obtained with the relevant HIV-specific or
CMV-specific populations. Freshly isolated PBMCs were incubated for 5 h
with targets pulsed with specific peptide or no peptide at different E/T
ratios: 100:1 (black bars), 200:1 (white bars), or 100:1 after partial deple-
tion of the tetramer-positive cells (hatched bars).72 Functional Studies of HIV-specific CD81 T Cells
This preserves the staining of the tetramer-positive popula-
tion so that their cytokine production can be measured.
Even though activation-induced TCR downregulation
probably still occurs, the fluorescent signal of internalized
tetramers can nevertheless be recorded. It has recently been
shown using confocal microscopy that tetramer internaliza-
tion can be detected within 15 min of incubation with a
virus-specific T cell clone at 378C (30).
Although the best method of stimulation is to use APCs
pulsed with specific peptide, it was striking that on their
own tetramers can activate antigen-specific CD81 T cells
to produce cytokines, and did so as efficiently as PHA or
OKT3. It is theoretically possible that some activation
might result from free peptide released by tetramers that
have spontaneously dissociated. Although other methods of
stimulation led to upregulation of CD69 and moderate
MIP-1b production, only antigen-pulsed APCs led to se-
cretion of both MIP-1b and IFN-g by the majority of tet-
ramer-positive cells. It is likely that other interactions be-
tween the APCs and CD81 T cells, such as adhesion and
costimulatory molecules, contribute to better stimulation of
cytokine release. The downregulation of CD8 was a con-
sistent feature of these activated T cells, and correlated
closely with the degree of activation and induced cytokine
release. It is intriguing that MIP-1b secretion was more
readily induced by suboptimal stimuli than IFN-g, which
highlights the potential for differential regulation of cyto-
kine secretion in antigen-specific T cells. This observation
emphasizes the complexity of the machinery and regulation
of T cell activation.
Using CTL clones to optimize our methodology, we
observed that the first cytokine released was TNF-a. This
is consistent with a recent study which demonstrated the
presence of preformed TNF-a mRNA in LCMV-specific
CD81 T cells (40). The kinetics of production of MIP-1b
and IFN-g were remarkably similar; moreover, all tet-
ramer-positive cells that produced MIP-1b also secreted
IFN-g and vice versa. MIP-1b therefore seems to show
the same secretion pattern as IFN-g, even though previ-
ous studies have suggested that it is stored in cytolytic gran-
ules complexed with sulfated proteoglycans, along with
granzyme A, RANTES, and MIP-1a (41). These data also
provide support for the use of ELISPOT assays that mea-
sure IFN-g in response to specific antigen to detect the
main population of antigen-specific CD81 T cells (5). In
contrast, a significant population of tetramer-staining cells
produced IFN-g and MIP-1b but not TNF-a; this shows
that different functional subsets of antigen-specific CD81 T
cells may exist. It has so far not been possible to character-
ize the TNF-a–negative population further in terms of
specific surface markers. These functional studies of tet-
ramer-staining cells provide a better method to study the
potential diversity among T cells responding to a particular
antigen than individual T cell clones, since these may not
be representative of the total responding T cell population,
which is likely to include cells that are unable to survive
and proliferate in tissue culture conditions (42).
These data provide the first clear evidence of the func-
tional capacity, with regard to cytokine secretion, of circu-
lating CD81 T cells specific for HIV and CMV antigens.
This is particularly relevant for the HIV-specific population,
as it has been proposed that these cells may be functionally
defective in HIV-infected individuals as a consequence of
inadequate CD41 T cell help (16). In a murine model of
LCMV infection in animals lacking CD4, CD81 T cells
elicited on LCMV challenge could be detected by tetramer
staining but lacked effector functions, including cytolysis
and IFN-g secretion, and failed to mediate viral clearance
(15). More recently, a population of CD81 T cells was
identified in a patient with metastatic melanoma, which
stained with tetrameric complexes of HLA-A2 and a mela-
noma peptide but failed to lyse melanoma target cells or se-
crete cytokines after mitogen stimulation (17). In contrast,
our studies show that the majority of HIV-specific and
CMV-specific CD81 T cells in peripheral blood are able to
Figure 7. Comparison between CMV-specific and HIV-specific
CD81 T cells for perforin and maturation markers. (A) Stainings for per-
forin, CD28, and CD27 were performed in CMV (B7 CMV) or HIV
(B8 Nef) specific CD81 T cell populations gated by means of specific tet-
ramers. Percentages of cells present in quadrants are shown. Data are rep-
resentative of 15 different stainings. (B) Inverse correlation between per-
forin and CD27 staining in HIV-specific and CMV-specific CD81 T
cells. Each dot represents perforin and CD27 staining for a single antigen-
specific CD81 T cell population. Framed dots (circle, square, or hexagon)
show specific populations belonging to the same donor.73 Appay et al.
produce a range of potent antiviral factors after stimulation
with specific antigen. In particular, this includes factors such
as MIP-1b and IFN-g that are known to have the capacity
to inhibit HIV replication (25, 43). This means that HIV-
specific T cells should be producing these factors at sites of
HIV replication in specific response to viral antigens. All of
the HIV-infected subjects studied were selected on the basis
of a previously identified population of tetramer-positive
cells: the majority were in the asymptomatic phase of
chronic infection. It is plausible that in the late stages of dis-
ease, when CD41 T cell help is even more limited, the cy-
tokine secretion of HIV-specific CD81 T cells could be less
efficient, as seen in two of our donors, H9 and H14. How-
ever, because of the requirement to be able to identify a
substantial tetramer-staining cell population in order to carry
out this kind of analysis, we have not yet been able to study
patients with progressive HIV infection. Recent studies of
HIV-infected subjects with chronic HIV infection, using a
flow cytometric assay of IFN-g production in response to
HIV antigens, have demonstrated that HIV-specific CD41
T cell responses are more readily detected than could be
measured previously using standard proliferation assays (44).
Although the cytokine secretion profile of HIV-specific
CD81 T cells is similar to that of CD81 T cells responding
to CMV, a striking difference is that the HIV-specific pop-
ulation expresses very little perforin. This is consistent with
a previous study showing that CD81 T cells infiltrating
lymphoid tissue in HIV-infected individuals have impaired
perforin expression (45).
We considered whether chronic stimulation of HIV-spe-
cific CD81 T cells in the infected patient could result in low
perforin levels as a consequence of repeated contact with vi-
rus-infected cells and subsequent degranulation. However,
there were no significant differences in the expression of the
markers for either early or late activation between HIV-spe-
cific and CMV-specific CD81 T cells. Furthermore even in
treated patients with optimal viral suppression on antiretrovi-
ral therapy, there was no restoration of perforin levels in the
HIV-specific CD81 population, nor did perforin expression
increase in HIV-specific CD81 T cells cultured in vitro in
the presence of IL-2 (data not shown).
Therefore, it is likely that HIV-specific CD81 T cells are
genuinely defective in perforin production, which could
render them less efficient at killing virus-infected cells. We
found that the degree of HIV-specific ex vivo lysis was
much lower than direct killing from CMV-specific cells in
the same donor, although the tetramer-positive populations
were of similar sizes. The observed correlation between ex
vivo lysis mediated by HIV-specific CD81 T cells and tet-
ramer staining (18) confirms that HIV-specific cells main-
tain some degree of lytic potential. However, the levels of
lysis elicited in this study (18) were relatively low (no more
than 5–10% specific lysis) for the numbers of tetramer-pos-
itive cells, and several patients had levels of A2 gag tetramer
staining of between 1 and 5% with no detectable ex vivo
lysis whatsoever. In contrast, the levels of ex vivo killing by
CMV-specific CD81 T cells isolated directly from periph-
eral blood are much higher (up to 40–50% specific lysis)
(17, 46). Although cytotoxicity mediated through Fas–FasL
interactions is an alternative route of target cell lysis, a re-
cent study has shown that virus-specific CTL clones lyse
HIV-infected T lymphocytes by means of the granule exo-
cytosis pathway (39), which is consistent with our observa-
tions using HIV-specific CTL clones (Appay, V., and T.
Dong, unpublished). The preservation of perforin staining
and functional activity in the CMV-specific CD81 T cells
of HIV-infected donors argues strongly against a general-
ized defect in perforin production in HIV infection.
The phenotype of the HIV-specific CD81 T cell popu-
lation we have described suggests that they may be imma-
ture effector cells, with a pattern of maturation markers that
lie in between those previously defined for memory and ef-
fector cells (37). This observation is in contrast to our find-
ings for CMV-specific CD81 T cells, which display a fully
mature effector phenotype (37). The main difference is the
persistent expression of CD27, a molecule from the TNF
receptor superfamily (47) that is expressed on thymic emi-
grants and upregulated on antigen-primed cells, but is not
usually expressed on differentiated effector cells (48). It is
possible that these cells are arrested in an immature and
functionally impaired stage of maturation due to a lack of
CD41 T cell help, as has recently been suggested (16). As
the initial loss of CD41 T cell help is specific for HIV anti-
gens (49), CMV-specific CD81 T cells would be unaf-
fected in early HIV disease and would therefore resemble
the CMV-specific CD81 T cell population seen in HIV-
uninfected donors.
In conclusion, HIV-specific CD81 T cells are functional
with regard to antiviral cytokine production in the asymp-
tomatic phase of HIV infection, and therefore could con-
tribute to the control of HIV replication to a certain ex-
tent. However, the defect in cytolytic function of these T
cells, which are apparently unable to mature into genuine
cytotoxic effector cells, could render them unable to elimi-
nate the virus. A better understanding of the mechanism
underlying this apparent block to the maturation of true
HIV-specific effector CD81 T cells could facilitate the sup-
pression and potentially even the clearance of the virus.
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